Johnson & Johnson's Q2 2022 earnings show continued strength across segments, despite macro challenges like inflation and COVID-related mobility restrictions.  Management highlighted strong performance in pharmaceuticals, driven by specific product successes like DARZALEX and TREMFYA,  and resilient MedTech results.  Guidance updates suggest a somewhat flat operating margin outlook for 2022, but the company expressed confidence in its ability to deliver long-term value.

[1]
